In Brief: SciGen, Institute of Drug Technology, Phosphagenics
Tuesday, 21 June, 2005
SciGen (ASX:SIE) has executed a commercialisation agreement with Rangs Pharmaceuticals for the commercialisation of insulin in Bangladesh. SciGen already has insulin commercialisation agreements in place for India, Pakistan and Sri Lanka.
The Institute of Drug Technology (ASX:IDT) will open and operate a second early phase clinical trial unit in Melbourne, in addition to its existing Adelaide based clinical unit CMAX. IDT anticipates the facility will be operational by August 2005.
A preclinical trial of Phosphagenics' (ASX:POH, AIM:PSG) drug delivery system TPM-01 has found successful delivery of the bio-active fragment of human parathyroid hormone through the skin. Parathyroid hormone is a naturally occurring polypeptide and can be used in the treatment of osteoporosis by daily injection. Phosphagenics has filed a new patent application to protect its discovery and now plans to conduct further trials using its drug delivery system for the delivery of insulin and other peptides.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
